Viridian Therapeutics, Inc.DE (VRDN) bonds
VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30257% above fair value
$30.12+0.06 (+0.20%)
Close on Nov 18, 2026Market cap $3.41BP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Viridian Therapeutics, Inc.DE reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2019
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Viridian Therapeutics, Inc.DE's 10-Q for the period ended Jun 30, 2026
| Issue | Coupon | Matures | Amount issued | Carrying value |
|---|---|---|---|---|
| Convertible Senior Notes Due 2032 Convertible at $25 a share | 1.75% | 2032 | $250.00M | $250.00M |
| Hercules Loan and Security Agreement | 8.95% | – | $300.00M | $50.00M |
| Sale of Future Revenue | – | – | $300.00M | – |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
See a number that looks wrong?